

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Resources Medical Holdings Company Limited

華潤醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1515)

COMPLETION OF MAJOR AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITIONS OF LH SUBJECT EQUITY, JE SUBJECT EQUITY AND JE SUBJECT DEBTS

This announcement is made by China Resources Medical Holdings Company Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated February 22, 2023 and May 17, 2023, respectively (the “**Announcements**”) and the circular of the Company dated April 27, 2023 (the “**Circular**”) all in relation to the major and connected transaction in relation to the acquisitions of the LH Subject Equity, JE Subject Equity and JE Subject Debts. Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Announcements and the Circular.

COMPLETION OF THE ACQUISITION OF THE LH SUBJECT EQUITY

The Board is pleased to announce that, based on the fulfillment of all conditions precedent to Completion of the acquisition of the LH Subject Equity on June 25, 2023 (the “**Completion Date I**”), the equity transfer registration in respect of the LH Subject Equity has been completed and the LH Subject Equity has been transferred to CR Hospital Investment pursuant to the Equity Transfer Agreement I. From the Completion

Date I, Liaoning CR Healthcare has become an indirect non-wholly owned subsidiary of the Company and Shenzhen CR Healthcare has become an indirect wholly owned subsidiary of the Company.

COMPLETION OF THE ACQUISITION OF JE SUBJECT EQUITY AND JE SUBJECT DEBTS

The Board is pleased to announce that, based on the fulfillment of all conditions precedent to Completion of the acquisition of the JE Subject Equity, on June 25, 2023 (the “**Completion Date II**”), the equity transfer registration in respect of the JE Subject Equity has been completed and the JE Subject Equity and JE Subject Debts have been transferred to CR Hospital Investment pursuant to the Equity and Debt Transfer Agreement II. From the Completion Date II, the JE Subject has become an indirect non-wholly owned subsidiary of the Company.

CONSOLIDATION ARRANGEMENT REGARDING THE LH SUBJECTS AND THE JE SUBJECT

As at the date of this announcement, the Company confirms that according to the International Financial Reporting Standards and the accounting policies of the Group, the Group will retrospectively consolidate the financial results of the LH Subjects and the JE Subject from June 2, 2022 (the date on which the Group, the LH Subjects and the JE Subject started to come under common control). The comparative data of the Group’s FY2022 financial statements (the “**Comparative Data**”) will be restated, that is, the financial results of the LH Subjects and the JE Subject from June 2, 2022 will be included in the Comparative Data. The Group’s FY2023 financial results will include the financial results of the LH Subjects and the JE Subject starting from January 1, 2023.

By order of the Board
China Resources Medical Holdings Company Limited
SONG Qing
Chairman

Shenzhen, June 30, 2023

As at the date of this announcement, the Board comprises Mr. SONG Qing, Mr. YU Hai, Mr. SHAN Baojie and Ms. YANG Min as executive Directors; Mr. HU Hui as non-executive Director; Mr. WU Ting Yuk, Anthony, Mr. KWONG Kwok Kong and Mr. FU Tingmei as independent non-executive Directors.